资源描述
Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,Cardiac Transplantation and Mechanical Circulatory Support,Andrew Boyle,MD,Associate Professor of Medicine,Medical Director of Heart Failure,Cardiac Transplantation,and Mechanical Circulatory Support,Division of Cardiology,University of Minnesota,Metabolic Stress Testing,Mancini D et al.,Circulation,1991;83:778-786.,Group 1:peak VO,2,14,Group 3:rejected for OHTx,AGE DISTRIBUTION OF HEART RECIPIENTS,(1/1982-6/2003),%of,Transplants,J Heart Lung Transpl.2004;23:796-803.,DIAGNOSIS IN ADULT HEART TRANSPLANTS,HEART TRANSPLANTATION,Kaplan-Meier Survival,(1/1982-6/2006),J Heart Lung Transplant 2008;27:937-983.,UMN Cardiac Transplant Survival,NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR,J Heart Lung Transplant 2008;27:937-983,Stevenson LW et al.Circulation 2003;108:492-7.,Inotropic Therapy for End-Stage Heart Failure,University of Minnesota VAD Implants,HeartMate II,Pulsatile vs Continuous Flow LVADs,Pulsatile/Volume Displacement,Continuous/Rotary,HeartMate II as BTT,Miller L,Boyle A,et al.,NEJM,2007;357:893.,HeartMate II BTT Clinical Trial,Adverse Event Rates,Adverse Event,HM II,(62 pt yrs),(n=133),HM VE,1,(86 pt yrs),(n=280),%reduction,Bleeding requiring surgery,0.78,1.47,47,Percutaneous lead infection,0.37,3.49,89,Stroke,0.19,0.44,57,Non-stroke neurological,0.26,0.67,61,RV failure requiring RVAD,0.08,0.30,73,Events/Patient Year,1,Frazier OH,et al.J Thor CV Surg 2001,Miller L,John R,Boyle A,et al.,NEJM,2007;357:893.,HM II as BTT in Women,Outcomes at one year,Pamboukian S,Boyle A,et al.,Circulation.,2008;118:S-1016,VentrAssist as Bridge to Transplant,VentrAssist Components,Implantable blood pump,Powered via percutaneous lead,Controller logs parameters&alarms,Battery or AC power supply,Laptop PC for clinician use,Blood pump,Outflow cannula,Controller and battery receptacle,Percutaneous lead,Inflow cannula,Summary,Total number of patients implanted,421,Longest support duration(d),1594,Mean support duration(d),219,Number of patients currently supported,180,VentrAssist Support Duration,6 months,192,12 months,67,24 months,16,Worldwide VentrAssist Experience*,*As of 3/3/09,Study Outcomes:Interim Analysis Population(n=98),Boyle A et al.ACC Late Breaking Clinical Trial 2009.,Newest VAD:Heartware,VADs vs CRT for NYHA Class IV Heart Failure,2 Year Mortality with CRT/CRT-D in NYHA Class IV Patients,Lindenfeld J et al.Circulation 2007;115:204-212.,COMPANION NYHA Class IV Patients,Lindenfeld J et al.Circulation 2007;115:204-212.,Improvement in Median Distance Walked in Six Minutes:HeartMate II vs CRT/CRT-D,Boyle A et al.Presented at ACC 2008.,Conclusions,Test to determine candidacy for transplant is metabolic stress test,Median survival post-transplant is 10 years,Frequency of transplantation is declining,Long term inotropic therapy not very successful,Continuous flow VADs show good long term survival with reduced adverse events,VADs now approved for BSA as low as 1.2,CRT for NYHA Class IV heart failure not terribly effective,
展开阅读全文